Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

Liver Transplantation

Volumn 21, Issue 6, 2015, Pages 823-830

  Gutierrez, Julio A ^a,b   Carrion, Andres F ^a   Avalos, Danny ^a   O'Brien, Christopher ^a   Martin, Paul ^a   Bhamidimarri, Kalyan Ram ^a   Peyton, Adam ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLATE MOFETIL; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; ANTIVIRUS AGENT;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GRAFT RECIPIENT; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INFECTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; ALLOGRAFT; DRUG COMBINATION; FIBROSIS; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; RECURRENT DISEASE; RETROSPECTIVE STUDY; VIROLOGY;

AGED; ALLOGRAFTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FIBROSIS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; SIMEPREVIR; SOFOSBUVIR;

EID: 84930034351     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24126     Document Type: Article

References (32)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB,; for American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
2. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J., The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008; 21: 459-465.
3. Berenguer M, Schuppan D., Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-1041.
4. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, et al., The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-1071.
5. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR., The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
6. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al., Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756.
7. Belli LS, Volpes R, Graziadei I, Fagiuoli S, Starkel P, Burra P, et al., Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Dig Liver Dis 2012; 44: 603-609.
8. Berenguer M., Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
9. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al., Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
10. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al., Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
11. Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, et al., Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014; 13: 525-532.
12. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al., Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
13. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al.,; for VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
14. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al., Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-408.
15. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al., Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413.
16. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al., Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426.
17. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al., Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-1679.
18. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al., Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117.
19. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al., Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765.
20. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C 2014. http://www.hcvguidelines.org. Accessed November 5, 2014.
21. Jansen Therapeutics. Olysio (simeprevir) full prescribing information. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed November 10, 2014.
22. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al., Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; doi: 10.1002/hep.27770. [Epub ahed of print]
23. Alsatie M, Chalasani N, Kwo PY., Management of hepatitis C infection after liver transplantation. Drugs 2007; 67: 871-885.
24. Gane EJ., The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (suppl 2): S36-S44.
25. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, et al., Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (pt 1): 852-858.
26. Joshi D, Pinzani M, Carey I, Agarwal K., Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 710-721.
27. Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P., Fibrosis progression in hepatitis C positive liver recipients after sustained virological response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007; 83: 351-353.
28. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al., Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199-207.
29. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al., Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000-1006.
30. Kawaoka T, Takahashi S, Kawakami Y, Tsuge M, Hiramatsu A, Imamura M, et al., Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. Hepatol Res; doi: 10.1111/hepr.12447.
31. Kiser JJ, Burton JR Jr, Everson GT., Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 596-606.
32. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al., An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382.